---
title: "Aspire Biopharma Announces 1-for-30 Reverse Stock Split"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286469924.md"
description: "Aspire Biopharma Holdings, Inc. has announced a 1-for-30 reverse stock split, effective May 11, 2026. This consolidation will merge every thirty pre-split shares into one post-split share, with no fractional shares issued. The trading symbol will remain ABSP, and a new CUSIP number will be assigned. This action aims to reduce the number of shares outstanding, potentially impacting share price dynamics and investor perception. Aspire Biopharma operates in the biopharmaceutical sector, with a current market cap of $6.26M and an average trading volume of 455,661."
datetime: "2026-05-14T21:12:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286469924.md)
  - [en](https://longbridge.com/en/news/286469924.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286469924.md)
---

# Aspire Biopharma Announces 1-for-30 Reverse Stock Split

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from Aspire Biopharma Holdings ( (ASBP) ) is now available.

On May 11, 2026, Aspire Biopharma Holdings, Inc. filed a Certificate of Amendment in Delaware to implement a 1-for-30 reverse stock split of its issued and outstanding common stock. The move consolidates every thirty pre-split shares into one post-split share, with no fractional shares issued and any resulting fractions rounded up to the nearest whole share.

The company’s trading symbol will remain ABSP, while its common stock will adopt a new CUSIP number, 738920305, once the reverse split becomes effective. The reverse split is expected to significantly reduce the number of shares outstanding, a capital markets action that can affect share price dynamics and investor perception of the company’s market position.

**More about Aspire Biopharma Holdings**

Aspire Biopharma Holdings, Inc. operates in the biopharmaceutical sector, though the company’s specific therapeutic focus and product portfolio were not detailed in the filing. Its common stock trades on the public markets under the ticker symbol ABSP, positioning the company within the broader life sciences and healthcare investment universe.

**Average Trading Volume:** 455,661

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $6.26M

### Related Stocks

- [ASBP.US](https://longbridge.com/en/quote/ASBP.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)